Key result
Dahuang-Shengjiang-Banxia Decoction targets diabetic kidney disease via 6 active ingredients and the VEGF/PI3K/AKT pathway.
Why the study?
The molecular mechanism of Dahuang-Shengjiang-Banxia Decoction in the treatment of diabetic kidney disease was not fully understood.
Population
Diabetic kidney disease molecular targets from multiple databases
Comparison
Dahuang-Shengjiang-Banxia Decoction active ingredients and their targets
Design
Network pharmacology and molecular docking study
Authors
Loading...
Highlights candidate DSBD targets in DKD; leaves open clinical translation pending prospective validation.
Network pharmacology and molecular docking suggest that Dahuang-Shengjiang-Banxia Decoction may treat diabetic kidney disease via the VEGF/PI3K/AKT signaling pathway.
Xu et al. (2024) studied diabetic kidney disease (DKD). Dahuang-Shengjiang-Banxia Decoction (DSBD) was evaluated. Dahuang-Shengjiang-Banxia Decoction targets diabetic kidney disease via 6 key active ingredients, including 6-gingerol and baicalin, and the VEGF/PI3K/AKT signaling pathway.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: